1-9 of 9
clinical pulmonary infection score
Close
Sort by
Journal Articles

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Anastasiya V Beynarovich, MD, Kirill Lepik, Nataliia Mikhailova, Elena Kondakova, Yuri Zalaylov, Evgeniya Borzenkova, Elena Babenko, Elena I Darskaya, MD PhD, Ivan S Moiseev, MD PhD, Axel Zander, Boris Afanasyev
Journal: Blood
Blood (2019) 134 (Supplement_1): 1561.
https://doi.org/10.1182/blood-2019-129076
Published: 2019
Journal Articles

Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT

Nikesh Dhiraj Chavda, MBBChir, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, Irma Khvedelidze, Hervé Finel, Saad Akhtar, MD, M S Rauf, MD, Nadira Durakovic, MD, Radovan Vrhovac, MD PhD, Maurizio Musso, MD, Pauline Brice, Mutlu Arat, MD, Didier Blaise, MD PhD, Matthew P. Collin, MD PhD, Joanna Romejko-Jarosinska, MD PhD, Aspasia Stamatoullas, MD, Zubeyde Nur Ozkurt, MD, Tadeusz Robak, MD, Björn E Wahlin, MD PhD, Keith Wilson, FRCPath, MRCP, MBBS, Eleonora Alma, Rocco Pastano, Luca Castagna, MD, Ali Bazarbachi, MD PhD, Hervé Ghesquieres, MD PhD, Andrei Colita, MD PhD, Silvia Montoto, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4018.
https://doi.org/10.1182/blood-2019-131410
Published: 2019
Journal Articles

The Inhibition of Platelets Restore Anti-Tumor Immune Response to Ovarian Cancer and Its Therapeutic Implication

Min Soon Cho, PhD, Omayra Gonzalez-Pagan, MD PhD, Karem Court Pinto, PhD, Anil Sood, MD, Vahid Afshar-Kharghan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3698.
https://doi.org/10.1182/blood-2018-99-116530
Published: 2018
Journal Articles

Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT

Betul Oran, MDMS, Guillermo Garcia-Manero, MD, Rima M. Saliba, PhD, Gheath Alatrash, DO, PhD, Elias J. Jabbour, MD, Uday Popat, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Jorge E. Cortes, MD, Amin M. Alousi, MD, Marina Y. Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Katy Rezvani, MD PhD, Mansour Alfayez, MD, Elizabeth J. Shpall, MD, Padmanee Sharma, MD PhD, Richard E Champlin, MD, Hagop M. Kantarjian, MD, Naval G. Daver, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 483.
https://doi.org/10.1182/blood-2018-99-115382
Published: 2018
Journal Articles

The New Landscape of Checkpoint Inhibitors in China

Chien-Shing Chen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5855.
https://doi.org/10.1182/blood-2018-99-111666
Published: 2018
Journal Articles

The Use of Checkpoint Inhibitors before and after Allogeneic Stem Cell Transplantion: A Double-Edged Sword

Ali Younas Khan, MD, Awais Ijaz, MD, Muhammad Usman, MD, Muhammad Junaid Tariq, MD, Muhammad Asad Fraz, MD, Muhammad Jahanzeb Khalil, MD, Ceren Durer, MD, Seren Durer, MD, Fnu Sagar, MD, Malik Qistas Ahmad, MD MBBS, Chaudhry Saad Sohail, MD, Zunairah Shah, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5722.
https://doi.org/10.1182/blood-2018-99-110006
Published: 2018
Journal Articles

Antibodies in Development for Multiple Myeloma: A Systematic Review

Muhammad Asad Fraz, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Nadia Carenina Nunes Cavalcante Parr, MD, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Muhammad Yasir, MD, Seren Durer, MD, Muhammad Jahanzeb Khalil, MD, Ceren Durer, MD, Sharoon Samuel, MBBS, Saher Nasir Amin, MD, Ahmad Safdar, Faiz Anwer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5656.
https://doi.org/10.1182/blood-2018-99-114224
Published: 2018
Journal Articles

Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in the Modern Era

Sridevi Rajeeve, MD, Gunjan L. Shah, MD, Craig H. Moskowitz, MD, Alison J. Moskowitz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2148.
https://doi.org/10.1182/blood-2018-99-116901
Published: 2018
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017